The Paycheck Protection Program (PPP), with over $500 billion distributed over a few months in 2020, was one of the largest stimulus programs in U.S. history. The program was created to help “small businesses” survive the COVID-19 shock. However, in a forthcoming RCFS paper, “Public Firm Borrowers of the U.S. Paycheck Protection Program,” Anna Cororaton and Samuel Rosen document that nearly half of U.S. public firms were eligible for the… Read More »Paper Spotlight: Public Firm Borrowers of the U.S. Paycheck Protection Program

The Editor’s Choice paper for issue 10(4) is “Public Firm Borrowers of the U.S. Paycheck Protection Program” by Anna Cororaton and Samuel Rosen. You can read the paper free online.

The Editorial Board has received 457 papers for the 2022 RCFS Winter Conference.

                          Recent estimates suggest that the cost of developing a single new drug in the biopharmaceutical sector is $2.6 billion, confirming the very large amounts of money that medical companies invest to develop a new treatment. Biomedical companies also face the risk of very low rates of success, not only due to the inherent scientific risk of developing… Read More »Paper Spotlight: Sharing R&D Risk in Healthcare via FDA Hedges

“Hidden Performance: Salary History Bans and Gender Pay Gap” by Jesse Davis, Paige Parker Ouimet, and Xinxin Wang